Amneal forms new wholly-owned subsidiary as Amneal Biosciences

Privately-held USA-headquartered generics manufacturer Amneal has announced the creation of Amneal Biosciences, which will be a wholly-owned subsidiary of Amneal Pharmaceuticals.

Amneal Biosciences will focus solely on the commercialization of high-barrier-to-entry generic and specialty pharma products such as injectables and biosimilars.

Chirag Patel, chairman and co-chief executive of Amneal, said: “Having a dedicated company focused on the unique needs and logistics of this market segment allows Amneal to guarantee the same level of quality and service to healthcare institutions and professionals that we deliver to our existing retail customers,” explains Amneal co-CEO and Chairman Chirag Patel, adding: “Amneal has a robust pipeline of both small-molecule injectable generics as well as biosimilars, and we expect to bring the first of these to market in early 2016. Our experienced Amneal Biosciences team provides the high degree of expertise these specialty products require.”